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Abstract
Background: Profilin-1 is an ubiquitous actin binding protein. Under pathological conditions such as diabetes, profilin-1
levels are increased in the vascular endothelium. We recently demonstrated that profilin-1 overexpression triggers indicators
of endothelial dysfunction downstream of LDL signaling, and that attenuated expression of profilin-1 confers protection
from atherosclerosis in vivo.
Methodology: Here we monitored profilin-1 expression in human atherosclerotic plaques by immunofluorescent staining.
The effects of recombinant profilin-1 on atherogenic signaling pathways and cellular responses such as DNA synthesis
(BrdU-incorporation) and chemotaxis (modified Boyden-chamber) were evaluated in cultured rat aortic and human coronary
vascular smooth muscle cells (VSMCs). Furthermore, the correlation between profilin-1 serum levels and the degree of
atherosclerosis was assessed in humans.
Principal Findings: In coronary arteries from patients with coronary heart disease, we found markedly enhanced profilin
expression in atherosclerotic plaques compared to the normal vessel wall. Stimulation of rat aortic and human coronary
VSMCs with recombinant profilin-1 (10
26 M) in vitro led to activation of intracellular signaling cascades such as
phosphorylation of Erk1/2, p70
S6 kinase and PI3K/Akt within 10 minutes. Furthermore, profilin-1 concentration-dependently
induced DNA-synthesis and migration of both rat and human VSMCs, respectively. Inhibition of PI3K (Wortmannin,
LY294002) or Src-family kinases (SU6656, PP2), but not PLCc (U73122), completely abolished profilin-induced cell cycle
progression, whereas PI3K inhibition partially reduced the chemotactic response. Finally, we found that profilin-1 serum
levels were significantly elevated in patients with severe atherosclerosis in humans (p,0.001 vs. no atherosclerosis or
control group).
Conclusions: Profilin-1 expression is significantly enhanced in human atherosclerotic plaques compared to the normal
vessel wall, and the serum levels of profilin-1 correlate with the degree of atherosclerosis in humans. The atherogenic effects
exerted by profilin-1 on VSMCs suggest an auto-/paracrine role within the plaque. These data indicate that profilin-1 might
critically contribute to atherogenesis and may represent a novel therapeutic target.
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Introduction
Diabetes and dyslipidemia are major risk factors for atheroscle-
rotic vascular disease. It remains however unclear how these
entities contribute to atherogenesis. Although diabetes is associated
with a marked accumulation of vascular smooth muscle cells
(VSMC) in fibroatheromas, representing an integral part of
atherosclerotic lesion progression, high glucose and insulin levels
do not directly induce VSMC proliferation and accumulation in
vivo [1]. It has been proposed that suppression of insulin signaling
in insulin resistance interferes with protective actions of insulin
such as endothelial NO production and anti-inflammatory effects
and thus leads to a chronic state of (pro)inflammation [2,3],
representing a hallmark of atherosclerosis [4]. Hyperglycemia can
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13608induce endothelial dysfunction and attenuates vascular endothelial
growth factor (VEGF) signaling in endothelial cells (ECs), thereby
impairing the regenerative capacity of the endothelium [3,5].
Finally, the pro-insulin cleavage product C-peptide may also
contribute to vascular dysfunction, as it co-localizes with
monocytes in early atherosclerotic lesions in type 2 diabetics,
and serves as a chemoattractant for human monocytes and a
mitogen for VSMCs [6,7]. While some mediators have thus been
identified, the exact cellular mechanisms that lead to accelerated
atherosclerosis remain poorly understood.
By screening of a peptide phage display library, we previously
identified profilin-1 as a binding partner for a diabetic aorta-
specific phage in rats [8]. Profilin-1 was increased in the
endothelium of diabetic animals, and its overexpression in cultured
ECs triggered indicators of endothelial dysfunction (apoptosis,
ICAM-1 expression, decreased NO signaling) [8]. More recently,
we specified the importance of profilin-1 for atherogenesis in vivo,
as profilin-1 heterozygosity conferred protection from atheroscle-
rosis in LDL receptor-null mice [9].
Profilin-1 is commonly recognized as an intracellular actin-
binding protein [10], which regulates the size, localization and
dynamics of unpolymerized actin in cells, and thus contributes to
cytoskeletal dynamics and actin-dependent cellular processes [11].
Intracellular profilin-1 interacts with many ligands such as actin,
the actin-related protein (Arp)2, gephyrin, phosphatidyl-inositol-
4,5-bisphosphate (PIP2), and diverse proteins comprising a poly-
proline stretch, i.e. VASP, p140mDia, and neuronal Wiscott-
Aldrich-Syndrome protein [12]. Through these interactions,
profilin-1 also serves as a signaling protein, transmitting external
signals from the cell surface to microfilaments [13]. However,
since there is also evidence for a pathogenic role of extracellular
profilin-1 in diseases states such as glomerulonephritis and after
endothelial damage [14,15], we now investigated whether profilin-
1 is present in human atherosclerotic plaques, and whether it
induces atherogenic responses in VSMCs.
Methods
Human tissue samples and immunofluorescence staining
Coronary arteries were collected from 8 adults with severe
coronary artery disease. All patients had an unfavorable risk
profile including diabetes/impaired glucose tolerance, hyperten-
sion, and dyslipidemia. Collections were approved by the local
Ethics Committee of the University of Cologne, and informed
consent was obtained from each patient. Segments of diseased or
undiseased regions were sampled and fixed in 4% formaldehyde
solution. Serial transverse sections were processed, and stained
with Elastin van Gieson (EvG) and Masson’s trichrome.
Immunofluorescence stainings were performed by incubating
deparaffinized sections with a rabbit anti-profilin-1 polyclonal
antibody (1:50), a monoclonal mouse anti a-smooth-muscle actin
(SMA) antibody (DAKO, Clone 1A4; 1:100) or a monoclonal
mouse anti von-Willebrand Factor (vWF) antibody (1:100).
Profilin-1, SMA and vWF were visualized by a Cy3-conjugated
(Jackson Immunoresearch, West Grove, PA, USA) and an Alexa
FluorH 488-conjugated secondary antibody (Molecular Probes,
donkey anti–mouse IgG), respectively. Nuclei were counterstained
with DAPI. Non-immune rabbit IgG was used as a negative
control in consecutive sections.
Synthesis and Purification of recombinant rat profilin and
human profilin
Full-length rat profilin subcloned into pQE-30 (Qiagen,
Valencia, CA, USA) downstream of a 6His-tag (kindly provided
by M. Tamura) was expressed in M15 E. coli as previously
described [8]. Profilin was purified under native conditions by
Ni
++ affinity chromatography using Ni-NTA agarose (Qiagen,
Valencia, CA, USA) according to the manufacturers instructions.
Human recombinant profilin-1 was purchased from Abcam.
Endotoxin levels in the profilin preparation were below the
detection threshold (,0.1 ng/mg) as assessed by the limulus assay.
Cell Culture and cellular responses
Rat VSMCs were isolated from thoracic aorta (Wistar Kyoto;
6–10 wk old; Charles River Wega GmbH, Sulzfeld, Germany) by
enzymatic dispersion and cultured as previously described
[16,17,18]. Human coronary VSMCs were purchased from Lonza
Biosciences (Vervier, Belgium) and maintained as recommended
by the manufacturer. Profilin-dependent DNA synthesis was
measured by a 5-bromodeoxyuridine (BrdU)-incorporation assay
as described [18]. Cells were synchronized by serum-deprivation
for at least 24 hours and stimulated with various concentrations of
recombinant profilin (1 nM–10 mM) for 24 hours. BrdU incorpo-
ration was measured after an incubation time of 16 hours.
Chemotaxis was assayed using a 48-well modified Boyden
chamber (NeuroProbe, Baltimore, MD) and PVP-free polycar-
bonate filters (8-mm pores) (Poretics, Livermore, CA) as described
[17]. Synchronized VSMCs were allowed to migrate for 5 hours at
37uC. Pharmacological inhibitors against PI 3-kinase (Wortman-
nin, LY294002), MEK (PD98059), Src family kinases (SU6656;
PP2), and PLCc (U73122) were purchased from Calbiochem.
Phosphorylation of signaling molecules
Subconfluent VSMCs were growth-arrested by serum depriva-
tion for 24 h and subsequently stimulated with recombinant
profilin-1 (up to 1 mM) for various time points in the presence or
absence of pharmacological inhibitors as indicated. The cells were
harvested, the lysates were resolved by SDS-PAGE, and subjected
to Western blotting as described [17,18], using antisera against
RasGAP (lysate control), phospho-Erk1/2 (thr202/tyr204), phos-
pho-Akt (ser473), or phospho-p70
S6K (Cell Signaling). The
Western blots were semi-quantitatively analyzed by densitometry,
and all data were normalized for RasGAP.
Quantitative real-time PCR
Profilin transcripts were measured ex vivo in carotid arteries
from 6-month-old male LDLR-deficient mice that were exposed to
chow or atherogenic diet for 3 months. RNA was isolated and
quantitatve real-time PCR was performed using SYBR green as
previously published [19]. Primer pairs were as follows: Profilin
forward (59-39): TTACGCCAGCTGAGGTTGGT; profilin re-
verse (59-39): CCACCGTGGACACCTTCTTT; 18S forward (59-
39): GGACTCTTTCGAGGCCCTGTA; 18S reverse (59-39):
CACCAGACTTGCCCTCCAAT. All animal experiments have
been performed according to national and international guide-
lines. The protocol for the animal experiments was submitted to,
and approved by, the local animal research authority.
Quantification of atherosclerosis in humans
104 patients undergoing coronary artery bypass grafting
(CABG) were stratified for aortic atherosclerosis, evaluated at 33
points along the arch, thoracic and abdominal aorta using
intraoperative ultrasound. Depending on the degree of aortic
atherosclerosis, individuals were clustered in three categories
according to the 33-point ultrasound score (0–7=None; 8–
20=Mixed; 21–33=Severe). 18 individuals without major
diagnosed diseases served as a control group.
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Profilin was immunoprecipitated from 400 ml of serum from
each patient (Santa Cruz; sc-166191), and Western blot analysis
was performed using an antibody that recognizes human profilin-1
(Cell Signaling; Ab3237). Semi-quantitative analysis was per-
formed using a series of dilution of recombinant profilin in the
same gel.
Statistical analysis
All data are expressed as means 6 SEM. Statistical analysis was
performed using paired or unpaired t test or one way analysis of
variance (ANOVA) followed by Newman-Keuls post-hoc test for
multiple comparisons as appropriate. P,0.05 was considered
statistically significant.
Results
Profilin-1 is expressed in human coronary atherosclerotic
plaques
Coronary arteries were obtained from 8 patients with coronary
artery disease who underwent heart transplantation. Profilin-1
expression was highly abundant within atherosclerotic lesions when
compared to the adjacent tissue (Fig. 1). Moreover, co-staining for
VSMCs (SMA) or endothelial cells (vWF) revealed that profilin-1
expression was not restricted to the endothelium, and profilin-1 was
also present in the extracellular space. Negative controls were
performed using non-immune IgG to rule out unspecific binding of
the profilin antibody (data not shown). Similar findings were
observed in all patients. In contrast to the abundant expression in
Figure 1. Expression of profilin in human atherosclerotic plaque. Analysis of consecutive sections from a coronary artery of a representative
patient with coronary artery disease. Upper panel: EvG and Masson’s trichrome staining at 406, inset was magnified at 1006. Middle and lower panels:
Immunofluorescence staining for profilin (red), a-smooth muscle actin (SMA, green), and von Willebrand Factor (vWF, green). DAPI-staining (blue) was
performed to visualize nuclei.
doi:10.1371/journal.pone.0013608.g001
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levels in non-atherosclerotic coronary arteries (Fig. 2).
Profilin-1 induces cellular responses and activates
classical signaling cascades in rat and human vascular
smooth muscle cells
To further evaluate whether extracellular profilin may have a
functional role within atherosclerotic plaques, we investigated its
ability to directly initiate cellular responses relevant to atherogen-
esis in VSMCs, such as cell cycle progression and migration via
activation of classical signaling cascades.
Stimulation of quiescent rat VSMCs with recombinant profilin-
1 led to a concentration-dependent increase of DNA synthesis to
maximally 3.960.6-fold at 1 mM compared to non-stimulated cells
(P,0.05) (Fig. 3A). Likewise, profilin-1 at 1 mM also induced
DNA synthesis 2.760.7-fold in human coronary VSMCs (P,0.05)
(Fig. 4A). Profilin-1 also dose-dependently induced the migration
of rat VSMCs to maximally 2.060.1-fold (P,0.01) (Fig. 3B)a s
well as the migration of human coronary VSMCs to 1.660.1-fold
(P,0.01) at 1 mM( Fig. 4B).
Growth factors induce cell cycle progression and chemotaxis in
various cell types via activation of classical signaling pathways such
as the PI 3-kinase (PI3K)/Akt (PKB) pathway, activation of Src
family kinases, phospholipase-Cc1 (PLCc), or the Ras-Raf-MEK-
Erk pathway, which ultimately leads to the phosphorylation/
activation of extracellular-regulated kinase 1/2 (Erk1/2). Stimu-
lation of VSMCs with recombinant profilin-1 (1 mM) led to a rapid
Figure 2. Low expression of profilin in normal coronary vessel. Analysis of consecutive sections from a representative coronary artery
without evident coronary artery disease. Upper panel: EvG and Masson’s trichrome staining at 406, inset was magnified at 1006. Middle and lower
panels: Immunofluorescence staining for profilin (red), a-smooth muscle actin (SMA, green), and von Willebrand Factor (vWF, green). DAPI-staining
(blue) was performed to visualize nuclei.
doi:10.1371/journal.pone.0013608.g002
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S6K within
15 minutes in both rat and human cells that was time- and
concentration-dependent (Fig. 3C and 4C/D). Profilin-induced
Erk phosphorylation was potently inhibited by the MEK1
inhibitor PD98059, whereas profilin-dependent Akt phosphoryla-
tion was inhibited by the PI3K inhibitors Wortmannin and
LY294002 (Fig. 3D), indicating that these downstream targets are
activated by profilin-1 via the classical Ras-Raf-MEK- and PI3K-
dependent pathways. It is interesting to note, that inhibition of
PI3K with Wortmannin or LY294002 potentiated Erk phosphor-
ylation. As expected, inhibitors of PLCc (U73122) or Src family
kinases (SU6656, PP2) did not affect Akt and Erk phosphorylation,
whereas the tyrosine kinase inhibitor genistein (Gen) slightly
inhibited profilin-dependent Erk activation.
Identification of intracellular signaling pathways that
mediate profilin-dependent cellular responses
To better understand the molecular mechanisms that mediate
profilin-induced DNA synthesis and migration in VSMCs, we
investigated these cellular responses in the presence of pharma-
cological inhibitors. Profilin-dependent cell cycle progression in rat
aortic VSMCs was almost completely abolished by the PI3K
inhibitors Wortmannin and LY294002 as well as the Src inhibitors
SU6656 and PP2, whereas inhibition of PLCc with U73122 did
not affect this cellular response (Fig. 3E). Inhibition of the Erk
pathway by PD98059 reduced BrdU uptake upon profilin-1
stimulation by approximately 50%. Similar results were obtained
in human coronary VSMCs (Fig. 4A). These data indicate that
profilin-dependent DNA synthesis requires PI3K, Src, and, to a
lesser extent, Erk1/2. The profilin-induced migration of VSMCs
was reduced by inhibition of PI3K (Wortmannin, LY294002),
whereas all other inhibitors had no effect, suggesting that the
chemotactic response requires only PI3K activity (Fig. 3F and
4B).
Correlation between profilin-1 levels and atherosclerosis
in vivo
To assess whether pro-atherosclerotic stimuli affect the
expression of profilin-1 in the vascular wall, the impact of
atherogenic diet on transcript levels of profilin-1 was investigated
in LDL receptor-deficient mice that were fed either chow or high
fat diet. As shown in Figure 5, there was a clear trend towards
increased levels of profilin-1 expression in animals that received
high fat diet and subsequently developed atherosclerosis. Although
this difference did not reach statistical significance, our data
suggest that there might be a link between pro-atherogenic stimuli
and vascular profilin-1 expression.
Importantly, we also assessed whether the serum levels of
profilin-1 were associated with the degree of atherosclerosis in
humans. To this end, patients undergoing coronary bypass surgery
were evaluated for the presence and severity of aortic atheroscle-
rosis by intraoperative ultrasound at 33 points along the arch,
thoracic and abdominal aorta, and the atherosclerosis score was
correlated to profilin-1 serum levels. We found that profilin levels
were significantly elevated in patients with the most severe aortic
atherosclerosis score (Figure 6), indicating that profilin-1 serum
levels were associated with the degree of atherosclerosis in
humans.
Discussion
The present study demonstrates that profilin-1 is highly
expressed in human atherosclerotic plaques, and – although
mainly recognized as an intracellular actin-binding protein –
serves as an extracellular ligand and induces atherogenic effects in
VSMCs such as DNA synthesis and migration. Furthermore,
profilin-1 activates classical signaling pathways including the
PI3K/Akt and Ras-Raf-MEK-Erk pathways. Profilin-induced
chemotaxis of VSMCs is dependent on PI3K activity, whereas
cell cycle progression requires multiple signaling pathways
including PI3K, Src, and Erk1/2, but not PLCc. Consistent with
our previous studies, these data indicate that profilin-1 may be
critically involved in the pathogenesis of atherosclerotic vascular
disease.
Individuals with coronary risk factors including type 2 diabetes
have a markedly elevated atherosclerotic risk [20]. The fact that
the incidence of both diabetes and atherosclerotic vascular disease
increases worldwide while diabetes-associated macrovascular
disease is already a major health care issue, stresses the need for
a better understanding of the pathomechanisms triggering
atherosclerosis. Our previous work demonstrated that profilin-1
is present on the luminal surface of the endothelium in human and
experimental diabetes, and that increased profilin-1 levels
triggered various indicators of endothelial dysfunction [8]. In
addition, LDL elevated profilin-1 levels in endothelial cells, which
may be important as local accumulation of LDL in lipid-laden
macrophages could further upregulate the expression of profilin-1
within plaques. Importantly, attenuation of profilin-1 expression
leads to decreased atherosclerotic lesion formation in mice [9].
The present study indicates that profilin-1 expression is markedly
elevated in human coronary plaques when compared to the
normal vessel wall, and that profilin-1 expression is not restricted
to the endothelium but is rather found throughout the plaque.
Profilin-1 partly co-localized with VSMCs, but was also found in
the extracellular space, as it may be released from ECs or
apoptotic cells. Hence, in addition to affecting the integrity and
function of endothelial cells, profilin-1 might also exert important
paracrine effects within atherosclerotic lesions and thereby
contribute to lesion progression.
The proliferation and migration of VSMCs are crucial events in
the development and progression of atherosclerotic lesions [1,4].
Quiescent VSMCs located in the media of undiseased arteries
proliferate at a low frequency, and are arrested in the G(0)/G(1)
Figure 3. Profilin induces cellular responses and activates classical signaling cascades in rat VSMCs. (A) DNA-synthesis as assessed by
measurement of BrdU incorporation. (B) Chemotaxis was evaluated utilizing modified Boyden chemotaxis chambers. (C) Quiescent VSMCs were
stimulated with recombinant profilin-1 (1 mM) for various time points as indicated. The cells were lysed, and equal amounts of protein were subjected
to SDS-PAGE and Western blot analyses, using phospho-specific antibodies recognizing phosphorylated p70
S6K, Akt, and Erk1/2. RasGAP served as a
lysate control. (D) Cells were stimulated with recombinant profilin-1 (1 mM) for 15 min in the presence of pharmacological inhibitors as indicated.
Data in C and D were quantified by densitometry and are expressed as fold increase compared to buffer-treated control cells. (E) DNA synthesis was
assessed by measurement of BrdU incorporation, and recombinant profilin was added in the presence of pharmacological inhibitors as indicated.
Data are expressed as the percentage of the maximal profilin-response. (F) Chemotaxis was evaluated utilizing modified Boyden chemotaxis
chambers in the presence of pharmacological inhibitors. Data are expressed as fold increase compared to buffer-treated control cells.
Pharmacological inhibitors: PI3K inhibitors wortmannin (W; 100 nM) and LY294002 (LY; 20 mM), MEK inhibitor PD98059 (PD; 30 mM), rapamycin (Rap;
10 nM), tyrosine kinase inhibitor genestein (Gen; 50 mM), Src inhibitors SU6656 (SU; 2.5 mM) or PP2 (50 nM), PLCc inhibitor U73122 (U; 10 mM). All data
represent means 6 SEM from at least three independent experiments. *P,0.05, **P,0.01 vs. control.
doi:10.1371/journal.pone.0013608.g003
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arterial injury, migration and subsequent proliferation of VSMCs
occurs, particularly in patients with type 2 diabetes [1,4,21].
Although diabetes is associated with VSMC accumulation in
developing lesions, hyperglycemia and hyperinsulinemia are
unable to directly induce VSMC proliferation or migration in vivo
Figure 4. Profilin induces cellular responses and activates classical signaling cascades in human coronary VSMCs. (A) DNA-synthesis
as assessed by measurement of BrdU incorporation in the absence or presence of inhibitors as indicated. Data are expressed as the percentage of the
maximal profilin-response. (B) Chemotaxis was evaluated utilizing modified Boyden chemotaxis chambers in the absence or presence of inhibitors as
indicated. Data are expressed as fold increase compared to buffer-treated control cells. See Figure 3 for inhibitors. Data in A and B represent means 6
SEM from at least three independent experiments. *P,0.05, **P,0.01 vs. control. (C and D) Quiescent VSMCs were stimulated with recombinant
profilin-1 (1 mM) for various time points and at various concentrations as indicated. The cells were lysed, and equal amounts of protein were
subjected to SDS-PAGE and Western blot analyses, using phospho-specific antibodies recognizing phosphorylated p70
S6K, Akt, and Erk1/2. RasGAP
served as a lysate control. Data in C and D were quantified by densitometry and are expressed as fold increase compared to buffer-treated control
cells.
doi:10.1371/journal.pone.0013608.g004
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and/or other mediators may be involved, and the classical risk
factors (e.g., obesity, hypertension, dyslipidemia) are likely to act in
concert with diabetes to promote the atherogenic process [2,3].
Our data indicate that one such mediator may be profilin-1, which
is known to be important for normal cell proliferation and
differentiation. Its gene disruption leads to embryonic lethality due
to grossly impaired growth, motility, and cytokinesis in single cells
[22,23,24]. We show that profilin-1 acts as a potent mitogen and
chemoattractant for VSMCs isolated from both rat aorta and
human coronary arteries. These findings are consistent with
previous studies demonstrating that profilin-1 is released into the
extracellular space in pathological conditions such as experimental
glomerulonephritis [14], and that profilin-1 exerts cellular
responses like DNA synthesis and upregulation of AP-1 DNA-
binding activity in mesangial cells via activation of cell surface
receptors [15]. Furthermore, in line with our results transgenic
overexpression of profilin-1 targeted to VSMCs caused vascular
hypertrophy and hypertension in mice, and this was associated
with significant increases in phospho-ERK1/2, phospho-JNK, and
phospho-ROCK II kinase in mouse aortas [25].
While our data and other studies indicate that profilin-1 may act
as an extracellular ligand, the mechanism of cellular activation
remains elusive. One study suggested that a protozoan profilin-like
protein activates a Toll-like receptor (TLR11) of dendritic cells
[26]. However, a similar mechanism in rodents or humans has not
been shown, so the role of Toll-like receptors in profilin signaling is
questionable at present. Another study demonstrated that
activation of DNA synthesis and AP-1 was associated with the
binding of profilin-1 to cell surface receptors in rat mesangial cells
[15]. Thus, although profilin may to act via a cell surface receptor,
a specific receptor has not yet been identified and cloned, and little
is known thus far about profilin signaling.
We have begun to identify the signaling pathways that mediate
profilin-dependent cellular responses in VSMCs. Using specific
pharmacological inhibitors, we found that profilin-dependent
DNA synthesis required multiple signaling events including
PI3K, Src, and Erk1/2 activity, whereas PLCc was not required.
These findings were not surprising, as PI3K, Src, and Erk1/2 were
previously shown to be involved in cell proliferation in response to
various stimuli [17,27,28]. Profilin-induced chemotaxis was
attenuated only by inhibition of PI3K, whereas the presence of
all other inhibitors did not affect the migratory response. This
finding is also consistent with other reports demonstrating that
PI3K signaling is critical for cellular motility and chemotaxis
[17,28].
Our further studies revealed that the vascular expression and
serum levels of profilin-1 are associated with atherosclerosis in vivo.
This was shown in LDLR-deficient mice in which the induction of
atherosclerosis by high fat diet led at least to a trend of increased
profilin-1 expression in the vessel wall, as found in human
atherosclerotic plaques. These data are accompanied by the
observation that patients with severe aortic atherosclerosis have
significantly increased profilin-1 serum levels. Although we did not
specifically correlate profilin levels with the severity of coronary
artery disease for technical reasons, all patients in the analysis were
admitted for CABG because of advanced coronary atherosclerosis,
but the degree of atherosclerosis could be reliably quantified in the
aorta. Nevertheless, the association between profilin-1 levels and
coronary atherosclerosis should be analyzed in a larger cohort of
patients in future studies.
In summary, we have demonstrated for the first time that
profilin-1 is highly expressed in human atherosclerotic plaques,
exerts direct atherogenic effects on VSMCs, and its serum levels
are associated with the degree of atherosclerotic vascular disease in
humans. Together with our previous reports, these data suggest
that profilin-1 may play a role in early and advanced stages of
atherosclerosis. Profilin-1 may therefore represent an important
novel target for therapeutic and preventive strategies against
atherosclerosis.
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the degree of aortic atherosclerosis was assessed by intraoperative
ultrasound at 33 points along the arch, thoracic and abdominal aorta.
According to the 33-point ultrasound score, individuals were clustered
into three categories (0–7=None; 8–20=Mixed; 21–33=Severe). The
control group is represented by 18 individuals without major diagnosed
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